Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration
Purpose To investigate the 4-year outcome of aflibercept treatment using a treat-and-extend (TAE) regimen for recurrent neovascular age-related macular degeneration (AMD). Study design Retrospective observational study. Methods Data of eyes with recurrent AMD previously treated with anti-vascular en...
Gespeichert in:
| Veröffentlicht in: | Japanese journal of ophthalmology 2021, Vol.65 (1), p.69-76 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 76 |
|---|---|
| container_issue | 1 |
| container_start_page | 69 |
| container_title | Japanese journal of ophthalmology |
| container_volume | 65 |
| creator | Tsunekawa, Yuma Kataoka, Keiko Asai, Keiko Ito, Yasuki Terasaki, Hiroko |
| description | Purpose
To investigate the 4-year outcome of aflibercept treatment using a treat-and-extend (TAE) regimen for recurrent neovascular age-related macular degeneration (AMD).
Study design
Retrospective observational study.
Methods
Data of eyes with recurrent AMD previously treated with anti-vascular endothelial growth factor agents or photodynamic therapy and had started aflibercept treatment using a TAE regimen for the first time were collected. Best-corrected visual acuity (BCVA), intervals of treatments, the presence of exudation, central foveal thickness (CFT), and central choroidal thickness (CCT) were analyzed.
Results
Of 47 consecutive eyes, 30 of the 47 eyes completed a 4-year follow-up. The mean BCVA (logMAR) was sustained over the 4 years (0.37 at baseline, 0.36 at 1 year, 0.36 at 2 years, 0.41 at 3 years, and 0.43 at 4 years, P = 0.21). Of the 30 eyes that completed the follow-up, BCVA of two eyes deteriorated by 0.3 logMAR or more at 4 years. At 4 years, 67% of eyes had extended treatment intervals to > 8 weeks, and 47% of eyes had extended intervals to > 12 weeks. Exudative changes in the macula, seen in all eyes at baseline, were only seen in 50% of the eyes at 4 years. The mean CFT and CCT decreased significantly at 4 years from 332 μm to 248 μm and from 218 μm to 183 μm, respectively.
Conclusion
In clinical settings, aflibercept treatment using a TAE regimen may successfully maintain visual acuity for up to 4 years even in recurrent cases of AMD. |
| doi_str_mv | 10.1007/s10384-020-00783-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2458723583</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2484107334</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-eebd53d1fcf431fb07a902e0bcc5cd6f7dbaff0f7395fe26f8f8bab82a0168893</originalsourceid><addsrcrecordid>eNp9kc1u1TAQhS1ERW9bXoAFssSGjcE_ceK7RFVLkSqxoetoYo-Dq8S52A5w34MHxiUFJBasRjP-5pyRDyEvBH8jOO_eZsGVaRiXnNXWKGaekJ1ohWJSNu1TsuNcCqaF1qfkLOd7znkjlXxGTpUSet8KsSM_rpc1sSNCosta7DIjXTwFP4UBk8VDoeDmEEMuCUpYIl1ziCMFWhJCYRAdw-8Fo6MJxzBjpCFSPGKm30L5XId2TQljoRGXr5DtOlUnGJElnKCgozNsM4cjRtxMLsiJhynj88d6Tu6urz5d3rDbj-8_XL67ZbZpdWGIg9PKCW99o4QfeAd7LpEP1mrrWt-5AbznvlN77VG23ngzwGAkcNEas1fn5PWme0jLlxVz6eeQLU4T1GvX3MtGm04qbVRFX_2D3tePi_W6SplG8E6pplJyo2xack7o-0MKM6RjL3j_kFm_ZdbXzPpfmfWmLr18lF6HGd2fld8hVUBtQK5PccT01_s_sj8BWSemAw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2484107334</pqid></control><display><type>article</type><title>Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration</title><source>SpringerLink Journals - AutoHoldings</source><creator>Tsunekawa, Yuma ; Kataoka, Keiko ; Asai, Keiko ; Ito, Yasuki ; Terasaki, Hiroko</creator><creatorcontrib>Tsunekawa, Yuma ; Kataoka, Keiko ; Asai, Keiko ; Ito, Yasuki ; Terasaki, Hiroko</creatorcontrib><description>Purpose
To investigate the 4-year outcome of aflibercept treatment using a treat-and-extend (TAE) regimen for recurrent neovascular age-related macular degeneration (AMD).
Study design
Retrospective observational study.
Methods
Data of eyes with recurrent AMD previously treated with anti-vascular endothelial growth factor agents or photodynamic therapy and had started aflibercept treatment using a TAE regimen for the first time were collected. Best-corrected visual acuity (BCVA), intervals of treatments, the presence of exudation, central foveal thickness (CFT), and central choroidal thickness (CCT) were analyzed.
Results
Of 47 consecutive eyes, 30 of the 47 eyes completed a 4-year follow-up. The mean BCVA (logMAR) was sustained over the 4 years (0.37 at baseline, 0.36 at 1 year, 0.36 at 2 years, 0.41 at 3 years, and 0.43 at 4 years, P = 0.21). Of the 30 eyes that completed the follow-up, BCVA of two eyes deteriorated by 0.3 logMAR or more at 4 years. At 4 years, 67% of eyes had extended treatment intervals to > 8 weeks, and 47% of eyes had extended intervals to > 12 weeks. Exudative changes in the macula, seen in all eyes at baseline, were only seen in 50% of the eyes at 4 years. The mean CFT and CCT decreased significantly at 4 years from 332 μm to 248 μm and from 218 μm to 183 μm, respectively.
Conclusion
In clinical settings, aflibercept treatment using a TAE regimen may successfully maintain visual acuity for up to 4 years even in recurrent cases of AMD.</description><identifier>ISSN: 0021-5155</identifier><identifier>EISSN: 1613-2246</identifier><identifier>DOI: 10.1007/s10384-020-00783-8</identifier><identifier>PMID: 33159611</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Acuity ; Age ; Age related diseases ; Clinical Investigation ; Exudation ; Eye ; Eye diseases ; Growth factors ; Intervals ; Macular degeneration ; Medicine ; Medicine & Public Health ; Ophthalmology ; Photodynamic therapy ; Thickness ; Vascular endothelial growth factor ; Visual acuity</subject><ispartof>Japanese journal of ophthalmology, 2021, Vol.65 (1), p.69-76</ispartof><rights>Japanese Ophthalmological Society 2020</rights><rights>Japanese Ophthalmological Society 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-eebd53d1fcf431fb07a902e0bcc5cd6f7dbaff0f7395fe26f8f8bab82a0168893</citedby><cites>FETCH-LOGICAL-c465t-eebd53d1fcf431fb07a902e0bcc5cd6f7dbaff0f7395fe26f8f8bab82a0168893</cites><orcidid>0000-0002-8795-6536</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10384-020-00783-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10384-020-00783-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33159611$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tsunekawa, Yuma</creatorcontrib><creatorcontrib>Kataoka, Keiko</creatorcontrib><creatorcontrib>Asai, Keiko</creatorcontrib><creatorcontrib>Ito, Yasuki</creatorcontrib><creatorcontrib>Terasaki, Hiroko</creatorcontrib><title>Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration</title><title>Japanese journal of ophthalmology</title><addtitle>Jpn J Ophthalmol</addtitle><addtitle>Jpn J Ophthalmol</addtitle><description>Purpose
To investigate the 4-year outcome of aflibercept treatment using a treat-and-extend (TAE) regimen for recurrent neovascular age-related macular degeneration (AMD).
Study design
Retrospective observational study.
Methods
Data of eyes with recurrent AMD previously treated with anti-vascular endothelial growth factor agents or photodynamic therapy and had started aflibercept treatment using a TAE regimen for the first time were collected. Best-corrected visual acuity (BCVA), intervals of treatments, the presence of exudation, central foveal thickness (CFT), and central choroidal thickness (CCT) were analyzed.
Results
Of 47 consecutive eyes, 30 of the 47 eyes completed a 4-year follow-up. The mean BCVA (logMAR) was sustained over the 4 years (0.37 at baseline, 0.36 at 1 year, 0.36 at 2 years, 0.41 at 3 years, and 0.43 at 4 years, P = 0.21). Of the 30 eyes that completed the follow-up, BCVA of two eyes deteriorated by 0.3 logMAR or more at 4 years. At 4 years, 67% of eyes had extended treatment intervals to > 8 weeks, and 47% of eyes had extended intervals to > 12 weeks. Exudative changes in the macula, seen in all eyes at baseline, were only seen in 50% of the eyes at 4 years. The mean CFT and CCT decreased significantly at 4 years from 332 μm to 248 μm and from 218 μm to 183 μm, respectively.
Conclusion
In clinical settings, aflibercept treatment using a TAE regimen may successfully maintain visual acuity for up to 4 years even in recurrent cases of AMD.</description><subject>Acuity</subject><subject>Age</subject><subject>Age related diseases</subject><subject>Clinical Investigation</subject><subject>Exudation</subject><subject>Eye</subject><subject>Eye diseases</subject><subject>Growth factors</subject><subject>Intervals</subject><subject>Macular degeneration</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Ophthalmology</subject><subject>Photodynamic therapy</subject><subject>Thickness</subject><subject>Vascular endothelial growth factor</subject><subject>Visual acuity</subject><issn>0021-5155</issn><issn>1613-2246</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1TAQhS1ERW9bXoAFssSGjcE_ceK7RFVLkSqxoetoYo-Dq8S52A5w34MHxiUFJBasRjP-5pyRDyEvBH8jOO_eZsGVaRiXnNXWKGaekJ1ohWJSNu1TsuNcCqaF1qfkLOd7znkjlXxGTpUSet8KsSM_rpc1sSNCosta7DIjXTwFP4UBk8VDoeDmEEMuCUpYIl1ziCMFWhJCYRAdw-8Fo6MJxzBjpCFSPGKm30L5XId2TQljoRGXr5DtOlUnGJElnKCgozNsM4cjRtxMLsiJhynj88d6Tu6urz5d3rDbj-8_XL67ZbZpdWGIg9PKCW99o4QfeAd7LpEP1mrrWt-5AbznvlN77VG23ngzwGAkcNEas1fn5PWme0jLlxVz6eeQLU4T1GvX3MtGm04qbVRFX_2D3tePi_W6SplG8E6pplJyo2xack7o-0MKM6RjL3j_kFm_ZdbXzPpfmfWmLr18lF6HGd2fld8hVUBtQK5PccT01_s_sj8BWSemAw</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Tsunekawa, Yuma</creator><creator>Kataoka, Keiko</creator><creator>Asai, Keiko</creator><creator>Ito, Yasuki</creator><creator>Terasaki, Hiroko</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8795-6536</orcidid></search><sort><creationdate>2021</creationdate><title>Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration</title><author>Tsunekawa, Yuma ; Kataoka, Keiko ; Asai, Keiko ; Ito, Yasuki ; Terasaki, Hiroko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-eebd53d1fcf431fb07a902e0bcc5cd6f7dbaff0f7395fe26f8f8bab82a0168893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acuity</topic><topic>Age</topic><topic>Age related diseases</topic><topic>Clinical Investigation</topic><topic>Exudation</topic><topic>Eye</topic><topic>Eye diseases</topic><topic>Growth factors</topic><topic>Intervals</topic><topic>Macular degeneration</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Ophthalmology</topic><topic>Photodynamic therapy</topic><topic>Thickness</topic><topic>Vascular endothelial growth factor</topic><topic>Visual acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tsunekawa, Yuma</creatorcontrib><creatorcontrib>Kataoka, Keiko</creatorcontrib><creatorcontrib>Asai, Keiko</creatorcontrib><creatorcontrib>Ito, Yasuki</creatorcontrib><creatorcontrib>Terasaki, Hiroko</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tsunekawa, Yuma</au><au>Kataoka, Keiko</au><au>Asai, Keiko</au><au>Ito, Yasuki</au><au>Terasaki, Hiroko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration</atitle><jtitle>Japanese journal of ophthalmology</jtitle><stitle>Jpn J Ophthalmol</stitle><addtitle>Jpn J Ophthalmol</addtitle><date>2021</date><risdate>2021</risdate><volume>65</volume><issue>1</issue><spage>69</spage><epage>76</epage><pages>69-76</pages><issn>0021-5155</issn><eissn>1613-2246</eissn><abstract>Purpose
To investigate the 4-year outcome of aflibercept treatment using a treat-and-extend (TAE) regimen for recurrent neovascular age-related macular degeneration (AMD).
Study design
Retrospective observational study.
Methods
Data of eyes with recurrent AMD previously treated with anti-vascular endothelial growth factor agents or photodynamic therapy and had started aflibercept treatment using a TAE regimen for the first time were collected. Best-corrected visual acuity (BCVA), intervals of treatments, the presence of exudation, central foveal thickness (CFT), and central choroidal thickness (CCT) were analyzed.
Results
Of 47 consecutive eyes, 30 of the 47 eyes completed a 4-year follow-up. The mean BCVA (logMAR) was sustained over the 4 years (0.37 at baseline, 0.36 at 1 year, 0.36 at 2 years, 0.41 at 3 years, and 0.43 at 4 years, P = 0.21). Of the 30 eyes that completed the follow-up, BCVA of two eyes deteriorated by 0.3 logMAR or more at 4 years. At 4 years, 67% of eyes had extended treatment intervals to > 8 weeks, and 47% of eyes had extended intervals to > 12 weeks. Exudative changes in the macula, seen in all eyes at baseline, were only seen in 50% of the eyes at 4 years. The mean CFT and CCT decreased significantly at 4 years from 332 μm to 248 μm and from 218 μm to 183 μm, respectively.
Conclusion
In clinical settings, aflibercept treatment using a TAE regimen may successfully maintain visual acuity for up to 4 years even in recurrent cases of AMD.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>33159611</pmid><doi>10.1007/s10384-020-00783-8</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-8795-6536</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-5155 |
| ispartof | Japanese journal of ophthalmology, 2021, Vol.65 (1), p.69-76 |
| issn | 0021-5155 1613-2246 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2458723583 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Acuity Age Age related diseases Clinical Investigation Exudation Eye Eye diseases Growth factors Intervals Macular degeneration Medicine Medicine & Public Health Ophthalmology Photodynamic therapy Thickness Vascular endothelial growth factor Visual acuity |
| title | Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T02%3A54%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Four-year%20outcome%20of%20aflibercept%20administration%20using%20a%20treat-and-extend%20regimen%20in%20eyes%20with%20recurrent%20neovascular%20age-related%20macular%20degeneration&rft.jtitle=Japanese%20journal%20of%20ophthalmology&rft.au=Tsunekawa,%20Yuma&rft.date=2021&rft.volume=65&rft.issue=1&rft.spage=69&rft.epage=76&rft.pages=69-76&rft.issn=0021-5155&rft.eissn=1613-2246&rft_id=info:doi/10.1007/s10384-020-00783-8&rft_dat=%3Cproquest_cross%3E2484107334%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2484107334&rft_id=info:pmid/33159611&rfr_iscdi=true |